On January 26, 2021 ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric and orphan drugs reported that it has received the support from the region Île-de-France as part of the PM’up program to accelerate the development of the company in Europe and the US (Press release, ORPHELIA Pharma, JAN 26, 2021, View Source [SID1234574283]). ORPHELIA Pharma will receive a grant of 250 000 € aimed at supporting the international development of the company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are grateful to receive the support from region Île-de-France which will allow us to accelerate the development of our medicines portfolio worldwide. Our products address unmet medical needs of life-threatening paediatric diseases and our ambition is to make them available to all patients", comments Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma.
"We will use the proceeds to implement the marketing operations of Kigabeq in Europe and continue the efforts in finding partners for key territories elsewhere", states Hugues Bienaymé, General Manager. "This program will also support the preparation of the US dossier and the evaluation of the market access strategy of Kimozo, the first paediatric drinkable formulation of temozolomide currently under development for the treatment of relapsed or refractory neuroblastoma", he adds.
About PM’Up program
The Région Ile-de-France supports the development of Small and Medium-sized Enterprises by providing financial assistance to support their growth strategy. PM’up is a grant of up to 250 000 € to finance a 3-year development plan. For more information, please visit View Source